A six-page summary of a meeting convened by amfAR and AVAC involving leaders from research and research sponsor agencies. The meeting reviewed the status of biomedical, behavioral and animal research relevant to intermittent PrEP, identifed gaps and priorities for moving forward.
Intermittent PrEP (iPrEP) Research Agenda: Summary of an amfAR/AVAC think tank
Next steps for PrEP: Getting a proven prevention option to the people who need it
An article from the June 2013 edition of the GMHC newsletter discussing issues of PrEP introduction worldwide, reviewing efficacy trial results and current status of regulatory approval of Truvada as PrEP and rollout efforts.
Women and Prevention Research: Designing, testing and marketing products to improve adherence
From AVAC’s Research & Reality webinar series, this recent webinar focused on essential questions about what recent trials do—and do not—tell us about whether women will want or use prevention tools including microbicide gels, rings and oral tenofovir-based PrEP.
Selected Trials of Long-Acting Injectables for Prevention and/or Treatment U=U of HIV
This Px Wire graphic from April-June 2014 Volume 7 No. 2 identifies selected trials of long-acting injectables in development for prevention and/or Treatment U=U of HIV.
A Three-Part Agenda for Ending AIDS 2014
The Px Wire centerspread from January-March Volume 7, No. 1 lays out the “research-to-rollout” continuum of steps between initial evaluations of a novel concept for HIV prevention and the ultimate introduction of new tool offered in an effective public health program.
The HIV Prevention Research-to-Rollout Continuum
AVAC Playbook 2013–2014: Global goals and priorities
The AVAC’s Playbook is a concise look at global goals related to ten areas that are critical to ending the AIDS epidemic. The squares contain long-term goals; in the circles we have laid out priorities for 2014. Working with our partners, we develop and implement advocacy strategies to get us closer to these goals.